

FORM 5

QUARTERLY LISTING STATEMENT

Name of CNSX Issuer: [Network Oncology Inc.](#) (the "Issuer").

Trading Symbol: The Issuer trades on the Canadian Securities Exchange under the symbol NOI and Deutsche Boerse Xetra - Frankfurt Stock Exchange: Symbol 2NY; WKN#: A11827.

This Quarterly Listing Statement must be posted on or before the day on which the Issuer's unaudited interim financial statements are to be filed under the *Securities Act*, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer's first, second and third fiscal quarters. This statement is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the CNSX.ca website.

General Instructions

- (a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.
- (b) The term "Issuer" includes the CNSX Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

There are three schedules which must be attached to this report as follows:

SCHEDULE A: FINANCIAL STATEMENTS

Financial statements are required as follows:

For the first, second and third financial quarters interim financial statements prepared in accordance with the requirements under Ontario securities law must be attached.

If the Issuer is exempt from filing certain interim financial statements, give the date of the exempting order.

The Issuer's consolidated financial statements are attached for the nine month period ended September 30, 2015. See Schedule A.

SCHEDULE B: SUPPLEMENTARY INFORMATION

The supplementary information set out below must be provided when not included in Schedule A.

1. Related party transactions

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

- (a) A description of the relationship between the transacting parties. Be as precise as possible in this description of the relationship. Terms such as affiliate, associate or related company without further clarifying details are not sufficient.
- (b) A description of the transaction(s), including those for which no amount has been recorded.
- (c) The recorded amount of the transactions classified by financial statement category.
- (d) The amounts due to or from Related Persons and the terms and conditions relating thereto.
- (e) Contractual obligations with Related Persons, separate from other contractual obligations.
- (f) Contingencies involving Related Persons, separate from other contingencies.

All related party transactions have been disclosed in the Issuer's condensed interim consolidated financial statements for the nine month period ended September 30, 2015, attached hereto as Schedule A and the Issuer's Management's Discussion and Analysis is attached for the nine month period ended September 30, 2015 attached hereto as Schedule B.

2. Summary of securities issued and options granted during the period.

Provide the following information for the period beginning on the date of the last Listing Statement (Form 2A):

- (a) summary of securities issued during the period,
-

Date of Issue	Type of Security (common shares, convertible debentures, etc.)	Type of Issue (private placement, public offering, exercise of warrants, etc.)	Number	Price	Total Proceeds	Type of Consideration (cash, property, etc.)	Describe relationship of Person with Issuer (indicate if Related Person)	Commission Paid
September 16, 2015	common shares	shares for assets	15,000,000* pre-reverse split shares	\$0.10 per share	\$1,500,000 deemed value	property	N/A	none
October 8, 2015	common shares	Warrant exercise	500,000 post reverse split shares	\$0.15 per share	\$75,000	cash	N/A	N/A

*On September 25, 2015, the Company completed a reverse share consolidation issuing one new share for each three old shares basis. The 15,000,000 pre-consolidation shares issued on September 16, 2015 became 5,000,000 shares post consolidation.

(b) summary of options granted during the period,

Date	Number	Name of Optionee if Related Person and relationship	Generic description of other Optionees	Exercise Price	Expiry Date	Market Price on date of Grant
Aug 17, 15	750,000	Manfred Nostitz	Management, Director	\$0.25	Aug 16, 2017	\$0.25
Aug 17, 15	500,000	Bill Thomas	Management, Director	\$0.25	Aug 16, 2017	\$0.25
Aug 17, 15	500,000	Alexander Goumenoiuk	Director	\$0.25	Aug 16, 2017	\$0.25
Aug 17, 15	250,000	Meris Kott	Consultant	\$0.25	Aug 16, 2017	\$0.25
Aug 17, 15	100,000	Adam Ross	Consultant	\$0.25	Aug 16, 2017	\$0.25
	2,100,000					

3. Summary of securities as at the end of the reporting period.

Provide the following information in tabular format as at the end of the reporting period:

- (a) description of authorized share capital including number of shares for each class, dividend rates on preferred shares and whether or not cumulative, redemption and conversion provisions,
- (b) number and recorded value for shares issued and outstanding,
- (c) description of options, warrants and convertible securities outstanding, including number or amount, exercise or conversion price and expiry date, and any recorded value, and
- (d) number of shares in each class of shares subject to escrow or pooling agreements or any other restriction on transfer.

A summary of securities has been provided in the Issuer's condensed interim consolidated financial statements for the nine month period ended September 30, 2015, attached hereto as Schedule A.

4. List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.

William Thomas, CFO, Secretary and Treasurer and Director
Manfred Nostitz, CEO, President and Director
Alexander P. Goumeniouk, Director

SCHEDULE C: MANAGEMENT DISCUSSION AND ANALYSIS

Provide Interim MD&A if required by applicable securities legislation.

The Issuer's Management's Discussion and Analysis is attached for the nine month period ended September 30, 2015. See Schedule B.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated: November 30, 2015.

William Thomas

Name of Director or Senior Officer

Signature

CFO, Director

Official Capacity

Issuer Details		For Quarter Ended	Date of Report
Name of Issuer		September 30, 2015	YY/MM/DD
Network Oncology Inc.			30/11/02
Issuer Address			
815 Hornby Street, Suite 605			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Vancouver, B.C. V6Z 2E6			(604) 649-5245
Contact Name		Contact Position	Contact Telephone No.
William Thomas		CFO	(604) 649-5245
Contact Email Address		Web Site Address	
admin@networklifesciencesinc.com		www.networklifesciencesinc.com	